Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine™, and to advance its pipeline of clinically-validated digital therapeutics.
Cricket Health Names New CEO Robert Sepucha, Secures $15 Million in Growth Capital from K2 HealthVentures to Expand Operations
Cricket Health, a comprehensive kidney care provider with a personalized, evidence-based approach to managing kidney disease, today announced that co-founder Arvind Rajan has been named Executive Chairman of the Board of Directors and Robert Sepucha has been appointed Rajan's successor as the company's CEO.The news comes as Cricket announces $15 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, which will help the company further expand its innovative kidney care model to more people across the country through additional payer partnerships.
COLORESCIENCE® ANNOUNCES SUCCESSFUL COMPLETION OF $30 MILLION DEBT FINANCING-SUPPORTING CONTINUED GROWTH IN CORE CHANNELS
Colorescience, an industry- leading, science-based, and health-focused skincare company announced today the successful completion of a $30 Million debt financing with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. This debt facility strengthens the Company’s balance sheet in a non-dilutive fashion and increases financial flexibility to support continued growth in its core channels
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it has received an aggregate of $71 million in gross proceeds from its at-the-market (“ATM") offering coupled with the execution of a $50 million debt financing facility with K2 HealthVentures (“K2HV”), a healthcare-focused specialty finance company.
VBI Vaccines Secures $50 Million Debt Financing From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
“This partnership with K2HV complements our recent $57.5 million equity raise, strengthening the financial position and flexibility of VBI as we advance our pipeline candidates through their next clinical and regulatory milestones, including the potential commercial launch of Sci-B-Vac® in the U.S., Europe, and Canada,” said Jeff Baxter, VBI’s president and CEO. “Throughout this investment process, the K2HV team has proven to have a deep understanding of our business and the science driving VBI, and we look forward to continued collaboration.”
Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced it has secured a debt financing facility for up to $45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of $15 million upon closing, a portion of which has been used to repay the remaining indebtedness that was outstanding under the Company’s prior credit facility. Two subsequent tranches totaling up to $30 million will become available to MTEM, at its option, upon the achievement of certain milestones with respect to the second tranche and, subject to lender consent and certain additional conditions with respect to the third tranche.
Inari Secures $45 Million Debt Financing to Bring Innovative Agriculture Technologies to Market
Inari, the biotechnology company developing next-generation seeds, announced that it has entered into a $45 million loan and security agreement with K2 HealthVentures (K2HV), a life sciences-focused investment firm.
The funds complement Inari’s recent $89 million equity raise and will be used to accelerate the development and commercialization of breakthrough gene-edited crops that address the challenges of climate change and improve productivity.
"Our alliance with K2HV enhances our financial position. It supports further expansion of our research and technology platform, as well as the development and commercialization of products that align sustainability with cutting-edge biotechnology,” said Ponsi Trivisvavet, chief executive officer of Inari. "The K2HV team has a strong understanding of our innovative approach to plant breeding and confidence in our vision of agriculture.”
Companion Medical Secures $27.5 Million Debt Financing from K2 HealthVentures
Companion Medical, Inc., an innovative diabetes company that developed the first and only FDA-cleared smart insulin pen and app system, today announced that it has entered into a loan and security agreement for up to $27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
"This financing enhances our financial flexibility as we continue to scale commercialization of our flagship product - InPen," said Sean Saint, chief executive officer of Companion Medical. "The K2HV team has a strong understanding of our innovative approach to diabetes management and the high-impact solution that InPen represents for people living with this disease. We are pleased to be able to partner with them on this transaction in support of our growth."